

IDENTIFICATION OF THE INHIBITORY  
ACTIVITY OF CARBAZOMYCINS B  
AND C AGAINST 5-LIPOXYGENASE,  
A NEW ACTIVITY FOR  
THESE COMPOUNDS

Sir:

In the course of our screening program for substances that inhibit the activity of 5-lipoxygenase (5-LPO) and potential as anti-inflammatory agents, we have identified a new biological activity for carbazomycins B and C.

The inhibitory effect of fermentation broth extracts was determined by measuring the amount of 5-hydroxy-eicosatetraenoic acid (5-HETE) produced in a cell free extract of RBL-1 cells (ATCC CRL 1378), in the presence of fermentation broth extracts, arachidonic acid, ATP, calcium chloride and glutathione. Quantitation of the 5-HETE produced was by liquid chromatography (Rainin Dynamax C18, 5 cm  $\times$  0.46 cm) with an HPLC solvent (85% methanol-29.2 mM lithium acetate buffer pH 6.3) at 1 ml/minute. Detection was at 230 nm with a Waters 481 detector and a Hewlett Packard 3396A integrator.

A fermentation broth extract from a microorganism, tentatively identified as a *Streptovercillium* species, showed significant 5-LPO inhibitory activity. For identification of the active species, fermentation broth was extracted with butanol. After removal of the solvent, the residue was reconstituted in acetonitrile-water (50:50) and subjected to HPLC and spectrophotometric detection as described previously<sup>1)</sup>. The effluent from the HPLC was collected in two 96 well microtiter plates as 200  $\mu$ l fractions. These were then evaporated to dryness, reconstituted in 10% DMSO-DULBECCO's phosphate buffered saline (PBS) and tested for 5-LPO inhibitory activity. Biological activity peaked at an elution time of 14.6 minutes, and the UV-visible spectrum obtained by diode array spectrophotometry was very similar, if not identical to that of carbazomycin B<sup>2,3)</sup>. The NMR spectrum of a semi-purified sample of the active compound was consistent with the carbazomycin B structure. The identity of the material as carbazomycin B was confirmed by both HPLC-thermospray MS of the sample and Tandem FAB-MS-MS with a (M+H)<sup>+</sup> ion at *m/z* 242. The fragmentation pattern on Tandem MS/MS was identical with an authentic sample of carbazomycin B obtained from M. KONISHI, Bristol-Myers Squibb Research Institute,

Table 1. Inhibition of 5-LPO.

Compound	IC <sub>50</sub> for inhibition of 5-LPO <sup>a</sup> ( $\mu$ M)
Carbazomycin B	1.5
Carbazomycin C	1.9
Butylated-hydroxytoluene	31.8
Hydroquinone	201.8
Carbazole	>>354.5

<sup>a</sup> RBL-1 cells were grown in DULBECCO's modified minimal essential medium with 20% heat-inactivated calf serum for 5 days at 37°C and 5% CO<sub>2</sub>. They were harvested by centrifugation and washed twice with DULBECCO's PBS containing 1 mM EDTA. The cells were resuspended in the same buffer and sonicated. The suspension was centrifuged at 13,000  $\times$  *g* to remove cell debris and the supernatant stored at -70°C. Enzyme assays were conducted by diluting the extract to the desired specific activity with DULBECCO's PBS containing 28.5 mM phosphate, 1 mM EDTA, 0.9 mM ATP and 0.9 mM glutathione. 110  $\mu$ l of the extract solution was preincubated at 37°C for 5 minutes, followed by the addition of the test substance in 20  $\mu$ l of 10% DMSO-PBS. The reaction was started by the addition of 5  $\mu$ l of substrate (2 mM arachidonic acid plus 25 mM calcium chloride in ethanol-water (3:1)). After incubation for 5 minutes the reaction was terminated by the addition of 110  $\mu$ l of ethanol and the solution centrifuged to remove precipitated protein. The supernatant was analyzed for 5-HETE by liquid chromatography as described.

Tokyo, Japan (*m/z* ions at 242, 227, 210, 182 and 167). A minor component of the fermentation was also noted at *m/z* 272, with a UV-spectrum also suggestive of a carbazole chromophore. Large scale fermentation of the organism, isolation of the active minor component and Tandem MS/MS indicated that this was carbazomycin C with a (M+H)<sup>+</sup> ion at *m/z* 272, which also showed 5-LPO inhibitory activity. The IC<sub>50</sub> values for carbazomycin B, carbazomycin C and a number of other 5-LPO inhibitors are shown in Table 1.

The 5-LPO inhibitory activity of these compounds is probably due to radical scavenger activity which is consistent with the recent report of carazostatin as a free radical scavenger<sup>4)</sup>. However, tests on carbazole itself and other compounds with a carbazole nucleus, but without a free phenolic hydroxyl group, gave poor 5-LPO inhibition. These results, to be published later<sup>†</sup>, suggest that the

<sup>†</sup> HOOK, D. J.; J. J. YACOBUCCI and S. O'CONNOR: Manuscript in preparation.

presence of such a free phenolic group may be essential for radical scavenging activity.

DEREK J. HOOK  
JOSEPH J. YACOBUCCI  
SEAN O'CONNOR  
MIKE LEE<sup>a</sup>  
ED KERNS<sup>a</sup>  
BALA KRISHNAN<sup>a</sup>  
JIM MATSON<sup>b</sup>  
GRACE HESLER<sup>b</sup>

Bristol-Myers Squibb Research Institute,  
Department of Screening and  
Biochemical Research,

<sup>a</sup>Department of Analytical Research,

<sup>b</sup>Department of Antitumor Chemistry,  
5 Research Parkway,  
Wallingford, CT 06492, U.S.A.

(Received May 21, 1990)

#### References

- 1) HOOK, D. J.; C. F. MORE, J. J. YACOBUCCI, G. DUBAY & S. O'CONNOR: Integrated Biological-Physicochemical system for the identification of antitumor compounds in fermentation broths. *J. Chromatogr.* 385: 99~108, 1987
- 2) SAKANO, K.; K. ISHIMARU & S. NAKAMURA: New antibiotics, carbazomycins A and B. I. Fermentation, extraction, purification and physico-chemical and biological properties. *J. Antibiotics* 33: 683~689, 1980
- 3) SAKANO, K. & S. NAKAMURA: New antibiotics, carbazomycins A and B. II. Structural elucidation. *J. Antibiotics* 33: 961~966, 1980
- 4) KATO, S.; H. KAWAI, T. KAWASAKI, Y. TODA, T. URATA & Y. HAYAKAWA: Studies on free radical scavenging substances from microorganisms. I. carazostatin, a new free radical scavenger produced by *Streptomyces chromofuscus* DC 118. *J. Antibiotics* 42: 1879~1881, 1989